Abstract | BACKGROUND: OBJECTIVES: To summarize current knowledge about neratinib (HKI-272), an oral, irreversible dual inhibitor of EGFR and HER2 and to define its future clinical role, especially in the context of related agents that are either available or in the pipeline. METHODS: CONCLUSIONS: Both preclinical and human studies have shown that neratinib has promising activity in both advanced breast cancer and NSCLC with an acceptable safety profile. The data support its continued clinical development.
|
Authors | Prithviraj Bose, Howard Ozer |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 18
Issue 11
Pg. 1735-51
(Nov 2009)
ISSN: 1744-7658 [Electronic] England |
PMID | 19780706
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Quinolines
- ERBB2 protein, human
- ErbB Receptors
- Receptor, ErbB-2
- neratinib
|
Topics |
- Animals
- Antineoplastic Agents
(adverse effects, pharmacology, therapeutic use)
- Breast Neoplasms
(drug therapy, physiopathology)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, physiopathology)
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Humans
- Lung Neoplasms
(drug therapy, physiopathology)
- Quinolines
(adverse effects, pharmacology, therapeutic use)
- Receptor, ErbB-2
(antagonists & inhibitors)
|